Dr Lenzo completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Western Australia. He received advanced training in general and nuclear medicine at Fremantle, Sir Charles Gairdner and Royal Perth Hospitals, and subsequently completed a fellowship in nuclear medicine at the University of Michigan. He is a Fellow of the Royal Australian College of Physicians (FRACP) and Australasian Association of Nuclear Medicine Specialists (FAANMS).
In 2015, Dr Lenzo founded Theranostics Australia, the nation’s first private theranostics practice, where he worked as a group clinical director and expanded the field of nuclear oncology globally. He has held notable positions including Head of Nuclear Medicine at Royal Perth Hospital, Head of the Western Australia PET Cyclotron Service at Sir Charles Gairdner Hospital, and Head of General Medicine at Fremantle Hospital. He is also the Founding Director of Cyclowest, a start-up company with a strong focus on patient care and cutting-edge innovative molecular imaging research to help bring the latest diagnostic and therapeutic radiopharmaceuticals to Perth and the Asia-Pacific region.
He is also an adjunct Clinical Professor in Medicine at Curtin University and Notre Dame University Australia and consultant physician at St John of God Hospital Murdoch. Dr Lenzo is a Board Member at radiopharmaceutical company, Glytherix, and holds advisory Roles with Telix Pharmaceuticals, Novartis Australia, 3BP, ANSTO and the University of Queensland Centre for Advanced Imaging.
Dr Lenzo maintains a strong interest in clinical research and has co-authored over 60 peer-reviewed publications specialising in molecular imaging and targeted therapies.
As Clinical Director, Molecular Imaging and Nuclear Oncology, Dr Lenzo leads Icon’s strategic direction and evolution of theranostics across Australia and internationally with a strong focus on patient-centred care and delivering new and emerging treatments to more people.